News & Updates

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023 byRoshini Claire Anthony

Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023
5α-reductase inhibitor treatment implicated in dementia
5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023

Men who are receiving treatment with 5α-reductase inhibitors (5-ARIs) are at increased risk of dementia in the immediate period after initiating treatment, a study has shown. Of note, both finasteride and dutasteride are associated with depression, but neither of them is linked to suicide.

5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023
Edoxaban prevents thromboembolism in children with cardiac disease
Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023

Edoxaban may be used as an alternative treatment for thromboembolism (TE) prevention in children with cardiac disease showing low rates of clinically relevant bleeding and TE, suggests a study. Some of its advantages include once-daily dosing and infrequent monitoring requirement.

Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
Parkinson’s, T2D drug affords cardioprotection in youth with T1D
31 Dec 2022 byJairia Dela Cruz

Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.

Parkinson’s, T2D drug affords cardioprotection in youth with T1D
31 Dec 2022